|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Nicardipine#Clinical Studies]] |
| {{Nicardipine}}
| |
| {{CMG}}; {{AE}}:{{AK}}
| |
| | |
| '''''For patient information about Nicardipine, click [[Nicardipine (patient information)|here]].'''''
| |
| | |
| ==CLINICAL STUDIES==
| |
| | |
| ===Effects In Hypertension===
| |
| | |
| In patients with mild to moderate chronic stable essential hypertension, Cardene I.V. (0.5 to 4.0 mg/hr) produced dose-dependent decreases in blood pressure. At the end of a 48-hour infusion at 4.0 mg/hr, the decreases were 26.0 mmHg (17%) in systolic blood pressure and 20.7 mmHg (20%) in diastolic blood pressure. In other settings (e.g., patients with severe or postoperative hypertension), Cardene I.V. (5 to 15 mg/hr) produced dose-dependent decreases in blood pressure. Higher infusion rates produced therapeutic responses more rapidly. The mean time to therapeutic response for severe hypertension, defined as diastolic blood pressure ≤95 mmHg or ≥25 mmHg decrease and systolic blood pressure ≤160 mmHg, was 77 ± 5.2 minutes. The average maintenance dose was 8.0 mg/hr. The mean time to therapeutic response for postoperative hypertension, defined as ≥15% reduction in diastolic or systolic blood pressure, was 11.5 ± 0.8 minutes. The average maintenance dose was 3.0 mg/hr.Deep vein thrombosis
| |
| <ref> {{cite web | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f8ef8420-01d2-11de-a455-0002a5d5c51b | title = CARDENE I.V. (nicardipine hydrochloride) injection, solution [EKR Therapeutics, Inc.] |accessdate = }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| {{FDA}}
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |